Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Comparison of persons who died of drug overdoses with and without evidence of hepatitis C, United States, 2019-2024

AI Summary
  • Decedents with hepatitis C were more often aged ≥55, non-Hispanic White, and had at least one recent touchpoint for intervention.
  • Proportion of overdose deaths with hepatitis C rose from 5.3% in July to December 2019 to 7.2% in July to December 2024.
  • Recommend community services, accessible hepatitis C testing, linkage to substance use disorder treatment and curative hepatitis C therapy, and enhanced surveillance.
Summarise with AI (MRCPsych/FRANZCP)

Drug Alcohol Depend. 2026 Aug 1;287:113295. doi: 10.1016/j.drugalcdep.2026.113295. Online ahead of print.

ABSTRACT

BACKGROUND: Injection drug use is the most common risk factor for hepatitis C virus (HCV) infection. Despite decreases in injection drug use among overdose decedents during 2020-2022, reported cases of newly-acquired hepatitis C remained relatively stable. This analysis compares sociodemographic characteristics and circumstances among overdose decedents with and without evidence of hepatitis C to inform prevention.

METHODS: CDC’s State Unintentional Drug Overdose Reporting System (SUDORS) collects data on unintentional and undetermined intent drug overdose deaths, including HCV infection information. Percentages of overdose deaths during July 2019-December 2024 with sociodemographic characteristics, drugs involved, and circumstances were calculated by hepatitis C evidence (48 jurisdictions). To assess trends, the percentage of overdose deaths with hepatitis C evidence was calculated by 6-month period from July 2019 to December 2024 (30 consistently reporting jurisdictions).

RESULTS: Among 328,754 decedents, compared to those without hepatitis C evidence (94.6%), those with hepatitis C evidence (5.4%) more often were aged ≥ 55 years (36.0% vs. 24.7%) and non-Hispanic White (75.9% vs. 63.9%), and had ≥ 1 recent touchpoint or potential intervention opportunity (e.g., mental health treatment, nonfatal overdose; 40.3% vs. 23.9%). The percentage with hepatitis C evidence increased from 5.3% during July-December 2019 to 7.2% during July-December 2024.

CONCLUSIONS: Implementing community-based services to prevent infectious disease spread and overdose, accessible hepatitis C testing, linkage to substance use disorder treatment and curative hepatitis C treatment, and robust public health surveillance to identify populations for tailored prevention efforts might help address hepatitis C and drug use epidemics.

PMID:42567116 | DOI:10.1016/j.drugalcdep.2026.113295

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD